Daunomac 20 Mg Inj

• Acute Myelogenous Leukemia (AML): Remission induction therapy in adult patients with acute nonlymphocytic/myelogenous leukemia.
• Acute Lymphocytic Leukemia (ALL): Remission induction therapy in child and adult patients as part of structured combination chemotherapy regimens.

• Patients with a known severe allergy or hypersensitivity to daunorubicin, other anthracyclines, or any of the inactive ingredients in the formulation.
• Individuals with severe pre-existing bone marrow suppression (extremely low blood counts) caused by past therapies.
• Patients with severe baseline heart disease, recent heart attack, or major heart rhythm disorders.
• Individuals who have reached the maximum cumulative lifetime limit for daunorubicin or other anthracyclines (such as doxorubicin).
• Pregnant or breastfeeding individuals.
• Patients with severe hepatic impairment or severe renal impairment, as specified by the applicable product information.

• Temporary Hair Loss (Alopecia): Significant hair thinning or loss, which generally regrows after treatment cycles end.
• Red-Discolored Urine: Your urine may turn reddish for 1 to 2 days after an infusion due to the colour of the medicine and its metabolites.
• Gastrointestinal Discomfort: Nausea, vomiting, reduced appetite, or loose stools.
• Mouth Soreness (Mucositis): Redness, tenderness, or small painful ulcers on the tongue, gums, or throat, developing a few days after treatment.

• Bone Marrow Suppression (Myelosuppression): A significant drop in white blood cells (increasing infection risk), red blood cells (causing severe anaemia and fatigue), and platelets (leading to easy bleeding or bruising).
• Heart Muscle Damage (Cardiotoxicity): High cumulative doses can weaken the heart muscle, leading to heart failure or abnormal heart rhythms. Symptoms include breathlessness, swollen ankles, or a rapid, pounding pulse.
• Infusion Site Leakage (Extravasation): If the liquid leaks out of the vein into surrounding tissue during infusion, it can cause local tissue injury, pain, and blistering.

• It must never be given intramuscularly, subcutaneously, or by mouth.
• The dose is determined based on body surface area, age, organ function, and the chemotherapy regimen.
• Immediately report burning, stinging, pain, swelling, or redness at the injection site, as these may indicate extravasation.

• Daunomac injection is stored and handled strictly by hospital pharmacies and oncology staff.
• Vials are maintained under the storage conditions specified by the manufacturer, protected from light exposure inside their outer packaging.
• Unused liquid, empty vials, and IV tubing are discarded in accordance with protocols for biohazardous cytotoxic drug disposal.

• Immediately report any fever, chills, sore throat, or unusual bleeding/bruising to your doctor.
• Expect your urine to turn reddish for a day or two after infusion; this is a known temporary effect of the medicine.
• Use a soft toothbrush and non-alcoholic, mild mouth rinses to protect delicate gums and prevent mouth sores.
• Inform your nurse immediately if you feel any pain, burning, or coldness near your IV line during treatment.
• Complete all scheduled heart monitoring tests (ECGs or echocardiograms) and routine blood tests requested by your oncologist.

Overdose

Missed a Dose

Interactions with other medicines

• Other Cytotoxic Agents / Radiation Therapy: Combining daunorubicin with other cancer therapies or chest radiation increases the risk of bone marrow suppression and cardiac toxicity.
• Cardiotoxic Drugs: Certain medications that affect heart function heighten the risk of heart muscle injury.
• Hepatotoxic / Nephrotoxic Drugs: Medicines that strain the liver or kidneys can slow the breakdown and clearance of daunorubicin, intensifying its toxicity.
• Live Vaccines: Live-attenuated vaccines must be avoided during treatment due to the risk of severe vaccine-derived infections in an immunocompromised body.

Interactions with food items

• Daunomac injection is delivered straight into your bloodstream; food does not affect its absorption or administration.
• Maintain adequate fluid intake as advised by your healthcare team, particularly if nausea or vomiting occurs.
• Avoid excessive alcohol consumption during treatment.